Spyre Therapeutics

Forecast & Rating18 analysts currently cover Spyre Therapeutics, with about 94.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $103.93, about 3.9% upside from the current price of $100.04. Price targets range from $78.00 to $135.00 — a wide spread, showing clear disagreement over just how much Spyre Therapeutics can rise. Historically, about 24.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Spyre Therapeutics closely still see room for the stock to rise. Data as of Jul 24, 2026; for reference only and not investment advice.